Browse Studies — Arctuva

Phase 1

A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy …

Relapsed Multiple MyelomaRefractory Multiple Myeloma

Estimated

~$10 – $8,750

Opna Bio LLCNCT06433947

Phase 2

Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination…

Refractory Multiple MyelomaRelapsed Multiple Myeloma

Estimated

~$10 – $7,500

Benjamin T Diamond, MDNCT05896228

Phase 1

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combinatio…

NHLMultiple MyelomaBlood Cancer+4 more

Estimated

~$10 – $8,750

Indapta Therapeutics, INC.NCT06119685

Phase 1

A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients w…

Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple Myeloma

Estimated

~$10 – $7,500

Alfred Chung, MDNCT06348108